anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An oral care composition comprising 40-80 % of one or more film forming polymers, 0.5-10 % of one or more bioadhesive agents, 0.5-8 % of one or more plasticisers, 2-35 % of one or more active agents, where one active agent is benzocaine, and another may be menthol, 5-20 % of one or more polymeric solvents in which the active agent is solubilised, and 0.5-15 % aqueous medium. The composition is in the form of a film of 50-500 µm thickness. The film forming polymer may be polyvinylpyrrolidone, pullulan, hydroxypropyl cellulose, or pectin. The bioadhesive agent may be a polycarbophil. The plasticiser may be glycerol. The polymeric solvent may be a polyalkylene glycol e.g. a polyethylene glycol. The composition may also comprise opacifiers such as titanium dioxide. Also described is a method of making an oral care composition comprising solubilising one or more active agents in one or more polymeric solvents while heating to 50-120 °C, then adding one or more of each of a: film-forming polymer, bioadhesive agent, plasticiser, and water. The composition is coated onto a backing sheet, forming a layer 100-500 µm thick, then dried to form a film which is 3-15 % water.
BACKGROUND: SLAMF1/CD150 is an active player in B cell signaling networks in chronic lymphocytic leukemia (CLL). CD150-mediated signaling initiates through a homophilic CD150 binding, which spans the adjacent cells, or the interaction with the soluble CD150 isoform (sCD150). The expression of sCD150 isoform at the mRNA and protein levels ex vivo was confirmed. However, it is unclear whether sCD150 isoform present in the blood plasma of CLL patients is a factor in the constitutive activation of CD150+ cells. The aim of this study was to develop an ELISA assay for the specific sCD150 evaluation and assess the sCD150 levels in the blood plasma of CLL patients with different CD150 expression on B cells.
MATERIALS AND METHODS: Blood plasma samples and peripheral blood mononuclear cells from 40 previously untreated CLL patients were analyzed. An ELISA method, ex vivo drug sensitivity assay, and a cell viability assay were used.
RESULTS: The sCD150 isoform was found in all studied plasma samples of CLL patients at different levels regardless of the cell surface CD150 expression status of B cells and sCD150 mRNA expression. CLL cases with low levels of the cell surface CD150 expression in B cells are characterized by high levels of sCD150 in blood plasma in contrast to the CLL cases with high cell surface CD150 expression on B cells. The elevated levels of sCD150 in blood plasma are associated with a better sensitivity of malignant B cells to cyclophosphamide and bendamustine.
CONCLUSIONS: The sCD150 isoform is actively secreted by CLL B cells with its accumulation in blood plasma, which may be regarded as an additional factor in the CLL clinicopathologic variability.
<P>PROBLEM TO BE SOLVED: To obtain a detergent for hair having even excellent sebum removing effects.  <P>SOLUTION: The detergent for hair comprises an anionic surfactant, an amphoteric surfactant and an amide condensate, or the like, of a fatty acid with a hydroxy(1-4C) alkylamine. 1,2-Pentanediol and 1,2-hexanediol are included in the detergent. The sum total of the contents of the 1,2-pentanediol and 1,2-hexanediol is preferably 0.1-5 wt.%, more preferably 0.5-3 wt.% based on the total amount of the subject cosmetic. The cosmetic comprises a polymer having a single amino acid residue and/or its salt in a preferred form as a preferable ingredient.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
BACKGROUND: Following critical illness, family members are often required to adopt caregiving responsibilities. Anxiety and depression are common long term problems for both patients and caregivers. However, at present, it is not known how the trajectories of these symptoms compare between patients and caregivers.
OBJECTIVES: The aim of this study was to investigate and compare the trajectories of anxiety and depression in patients and caregivers in the first year following critical illness.
METHODS: This study analyses data from a prospective multicentre cohort study of patients and caregivers who underwent a complex recovery intervention following critical illness. Paired patients and caregivers were recruited. The Hospital Anxiety and Depression Scale was used to evaluate symptoms of anxiety and depression at three timepoints: baseline; 3 months; and 12 months in both patient and caregivers. A linear mixed-effects regression model was used to evaluate the trajectories of these symptoms over the first year following critical illness.
RESULTS: 115 paired patients and caregivers, who received the complex recovery intervention, were recruited. There was no significant difference in the relative trajectory of depressive symptoms between patients and caregivers in the first 12 months following critical illness (p = 0.08). There was, however, a significant difference in the trajectory of anxiety symptoms between patients and caregivers during this time period (p = 0.04), with caregivers seeing reduced resolution of symptoms in comparison to patients.
CONCLUSIONS: Following critical illness, symptoms of anxiety and depression are common in both patients and caregivers. The trajectory of symptoms of depression was similar between caregivers and patients; however, there was a significantly different recovery trajectory in symptoms of anxiety. Further research is required to understand the recovery pathway of caregivers in order to design effective interventions.
This study is designed as an observational, cross-sectional investigation at the National University Hospital and Alexandra Hospital. The research aims to enroll 50 eligible patients in each of the three groups (OSA treated, OSA untreated, and non-OSA, totaling 150 participants). The recruited participants will undergo ambulatory blood pressure monitoring (ABPM) and the Montreal Cognitive Assessment (MoCA). ABPM is a widely used, noninvasive method to determine patients' blood pressure control. MoCA is a widely used screening tool designed to assess cognitive function and detect mild cognitive impairment or early signs of dementia. The MoCA evaluates various cognitive domains, including attention, memory, language, visuospatial abilities, executive functions, and orientation. It consists of a series of tasks and questions that assess different aspects of cognitive functioning, such as drawing specific shapes, recalling words or numbers, and performing simple calculations. A trained healthcare professional will administer the digital version of the MoCA, which usually takes less than 30 minutes to complete. The MoCA has been validated for use in diverse populations and has shown good sensitivity in detecting mild cognitive impairment. The maximum score on the MoCA is 30. Lower scores may indicate potential cognitive impairment.
BACKGROUND: Breast cancer patients with residual disease after neoadjuvant systemic treatment (NAST) have a worse prognosis compared with those achieving a pathologic complete response (pCR). Earlier identification of these patients might allow timely, extended neoadjuvant treatment strategies. We explored the feasibility of a vacuum-assisted biopsy (VAB) after NAST to identify patients with residual disease (ypT+ or ypN+) prior to surgery.
METHODS: We used data from a multicenter trial, collected at 21 study sites (NCT02948764). The trial included women with cT1-3, cN0/+ breast cancer undergoing routine post-neoadjuvant imaging (ultrasound, MRI, mammography) and VAB prior to surgery. We compared the findings of VAB and routine imaging with the histopathologic evaluation of the surgical specimen.
RESULTS: Of 398 patients, 34 patients with missing ypN status and 127 patients with luminal tumors were excluded. Among the remaining 237 patients, tumor cells in the VAB indicated a surgical non-pCR in all patients (73/73, positive predictive value [PPV] 100%), whereas PPV of routine imaging after NAST was 56.0% (75/134). Sensitivity of the VAB was 72.3% (73/101), and 74.3% for sensitivity of imaging (75/101).
CONCLUSION: Residual cancer found in a VAB specimen after NAST always corresponds to non-pCR. Residual cancer assumed on routine imaging after NAST corresponds to actual residual cancer in about half of patients. Response assessment by VAB is not safe for the exclusion of residual cancer. Response assessment by biopsies after NAST may allow studying the new concept of extended neoadjuvant treatment for patients with residual disease in future trials.
Parkinson's disease (PD) exhibits heterogeneity in terms of symptoms and prognosis, likely due to diverse neuroanatomical alterations. This study employs a contrastive deep learning approach to analyze Magnetic Resonance Imaging (MRI) data from 932 PD patients and 366 controls, aiming to disentangle PD-specific neuroanatomical alterations. The results reveal that these neuroanatomical alterations in PD are correlated with individual differences in dopamine transporter binding deficit, neurodegeneration biomarkers, and clinical severity and progression. The correlation with clinical severity is verified in an external cohort. Notably, certain proteins in the cerebrospinal fluid are strongly associated with PD-specific features, particularly those involved in the immune function. The most notable neuroanatomical alterations are observed in both subcortical and temporal regions. Our findings provide deeper insights into the patterns of brain atrophy in PD and potential underlying molecular mechanisms, paving the way for earlier patient stratification and the development of treatments to slow down neurodegeneration.
An integrated system for processing and using images acquired of subjects in a research or clinical environment is provided. The integrated system includes an image and data bank, a workflow management module, a cloud storage module and a pre-processing module. The pre-processing engine is positioned between the workflow management module and the cloud storage module and is configured to receive raw images, data associated with the raw images and the data associated with the imaged subjects from the workflow management module and process this data and provide the processed data to be pushed into the cloud storage module. The pre-processing engine also anonymizes the data to provide de- identified images and data to the cloud storage module and creates a key that relates the raw images, data associated with the raw images and the data associated with the imaged subjects to the de- identified, processed images and data. The key remains separate and un-connected from the de-identified, processed images and data. The key allows the de-identified, processed images and data to maintain traceability to the imaged subjects and to all subsequent operations on the images and data.
Aims/Background The application of immunochemotherapy has significantly enhanced the quality of life and overall survival of patients with esophageal cancer. Sarcopenia, which is increasingly prevalent in these patients, markedly affects prognosis, but can be reversed by appropriate and effective treatment. Methods The narrative review was conducted on PubMed using the keywords ("esophageal" or "esophagus" and "sarcopenia"). Results This article reviews the measurement, timing, and intervention strategies for sarcopenia in patients with esophageal cancer. It summarizes the evaluation indicators of skeletal muscle loss in these patients, analyzes the barriers to intervention for frailty among esophageal cancer patients, and proposes corresponding countermeasures. Conclusion Patients with esophageal cancer often suffer from severe sarcopenia. Clinical intervention is crucial in addressing this issue.
Menadione bisulphite salts are stabilized by mixing them with monocalcium phosphate or with a mixture of mono- and di-calcium phosphates, and then granulating the compositions. The salt may be menadione sodium bisulphite. For each part by weight of menadione bisulphite salt there is used from 1 to 2 parts by weight of monocalcium phosphate, or 9 to 36 parts by weight of monocalcium phosphate and 1 part by weight of dicalcium phosphate. A solution of a binder may be added to the mixture and the mass kneaded, dried and granulated.ALSO:Animal feeds, especially poultry feeds, contain granules of menadione bisulphite salt, e.g. menadione sodium bisulphite, stabilized with monocalcium phosphate or a mixture of mono- and dicalcium phosphates.  Examples are given.
The object of the present invention is solved by compositions of peptide linkers and their use for synthesis and annealing of aptamer oligonucleotides in form of dimers. The present invention in particularly provides said compositions for the use as a diagnostic and/or therapeutic agent. In another preferred embodiment the present invention relates to a kit for preparing a radio pharmaceutical preparation, said kit comprising a vial comprising a quantity of the compound according to the invention. A further preferred embodiment of the present invention relates to methods of producing said compounds, comprising synthesis of said compound in an automated peptide synthesizer. In another preferred embodiment the present invention concerns the use of said compounds according to the present invention for the manufacture of a medicament, preferably for diagnosis or therapy of proliferative diseases. In a further preferred embodiment the present invention concerns methods for treating or diagnosing patients administering or utilizing the compounds according to the present invention.
The control group is designed to assess for potential effects on outcomes of time, attention, during the study. In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups. They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support. They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.
BACKGROUND: Human papillomavirus (HPV) infections can cause cancers of the cervix, vagina, vulva, penis, anus, and oropharynx. The most recently approved HPV vaccine, Gardasil-9, protects against HPV infection and can prevent HPV-associated invasive cancers. However, Gardasil-9 is one of the most underused vaccines in the US today. Young adults are at risk for HPV infection, but many are not vaccinated. This study uses a randomized controlled trial (RCT) to test an innovative multilevel intervention to increase HPV vaccination rates among young adults. In this paper, we describe the research protocol.
METHODS: The study uses a two by three factorial design. A total of 1200 young adults in Texas, age 18-26 years, who have not been previously fully vaccinated against HPV will be randomly assigned to one of six conditions to receive: (1) standard CDC information about HPV vaccination (control); (2) video narratives about HPV vaccination; (3) written narratives about HPV vaccination; or (4-6) enhanced access to HPV vaccine combined with (4) standard CDC information, (5) video narratives, or (6) written narratives. The two primary outcomes are the rate of HPV vaccination initiation by 3-month follow-up and rate of HPV vaccination completion by 9-month follow-ups. We will determine the impact of the individual level intervention (i.e., persuasive narratives through video or written format), the systemic level intervention (i.e., enhanced access to HPV vaccines), and the combination of both levels, on HPV vaccination initiation and completion. We will also use purposive sampling to select participants to take part in semi-structured interviews/focus groups to better understand the mechanisms of the intervention.
DISCUSSION: Recruitment and data collection began in March 2022. We expect to complete data collection by March 2026. We expect that narratives, enhanced access, and the combination of both will improve HPV vaccination initiation and completion rates among young adults. If proven successful, these individual- and system-level interventions can be easily disseminated in regions with low HPV vaccination rates to improve HPV vaccination, and ultimately decrease HPV-related cancer burden.
TRIAL REGISTRATION: NCT05057312.
The present invention relates to a chemical and pharmaceutical technology, and in particular to a STAT3 and ERK signal pathway inhibitor and a use thereof. The present invention provides a STAT3 and ERK signal pathway inhibitor. The inhibitor mainly consists of a mogroside and/or an analog thereof. The mogroside and the analog thereof inhibit the phosphorylation of a transcription factor STAT3 and the phosphorylation of an ERK. The method for preparing the mogroside and the analog has the characteristics of simpleness, strong operability and high purity of products. The present invention furtherprovides a use of the STAT3 and ERK signal pathway inhibitor in the preparation of drugs for treating tumors, which realizes the purposes of inhibiting the proliferation of cancer cells and promoting the apoptosis of cancer cells and has a very good inhibition effect on cancers.
Patients undergo a single fraction of BgRT on day 0. Patients undergo PET/CT on study and optionally during follow up.
Controlled clinical studies of metformin hydrochloride extended-release tablets did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients (see Error! Hyperlink reference not valid., Error! Hyperlink reference not valid., and Error! Hyperlink reference not valid.)
Obesity is a heterogeneous problem and research has highlighted the particular significance of a subgroup with binge-eating disorder (BED), the most prevalent formal eating disorder. This study examined the effectiveness of two leading but distinct treatments - lisdexamfetamine (LDX) and cognitive behavioral therapy (CBT) - alone and in combination, for BED in patients with obesity. LDX is the first and only FDA-approved medication for the treatment of BED and has demonstrated short-term effectiveness relative to placebo. CBT is the best-established psychological treatment, has demonstrated short-term effectiveness and "treatment specificity" (i.e., superiority to a variety of control and active treatments), has shown longer-term superiority to fluoxetine, and longer-term durability of outcomes. N=180 participants with BED and obesity will be randomly assigned to one of three interventions, CBT alone, LDX alone, or CBT combined with LDX. This RCT will provide new findings regarding the relative effectiveness of LDX, CBT, and combined CBT+LDX for patients with obesity and BED. No such study has been performed.
The invention discloses a pseudorabies virus canine animal isolate, and an inactivated vaccine prepared from the pseudorabies virus canine animal isolate and application of the pseudorabies virus canine animal isolate. The invention firstly discloses a pseudorabies virus canine animal isolate PRV-LN strain, the microorganism preservation number of which is as follows: CGMCC No. 14736. The invention further discloses application of the PRV-LN strain in preparation of a vaccine for preventing the anti-fake rabies, in particular to the anti-fake rabies vaccine for canine pseudorabies. The invention also discloses a vaccine composition for preventing the pseudorabies of the canine animals, which comprises the following components in part by weight: a prophylactically effective amount of an inactivated PRV-LN strain and a pharmaceutically acceptable adjuvant. The inactivated vaccine prepared by the pseudorabies virus PRV-LN strain has a good immune effect, and can better prevent and control the pseudorabies of the canine animals. The pseudorabies virus PRV-LN strain separated by the invention can be used as a candidate vaccine strain for preventing and controlling the pseudorabies of the canine animals.
INTRODUCTION: Anticholinergic agents are commonly taken in overdose, often causing delirium. The spectrum of anticholinergic delirium ranges from mild agitation to severe behavioural disturbance. Physostigmine is an effective treatment for anticholinergic delirium, but its availability is limited. As rivastigmine is readily available, it has been used to manage anticholinergic delirium; however, there is limited research investigating its use.
METHOD: This was a retrospective review of patients with anticholinergic delirium treated in two toxicology units with rivastigmine (oral capsule or transdermal patch) from January 2019 to June 2023. The primary outcome was the use of further parenteral treatment (sedation or physostigmine) for delirium post rivastigmine administration.
RESULTS: Fifty patients were administered rivastigmine for the management of anticholinergic delirium. The median age was 36 years (interquartile range: 25-49 years) and 27 (54 per cent) were females. Features consistent with anticholinergic toxicity included tachycardia in 44 (88 per cent) and urinary retention requiring catheterisation in 40 (80 per cent). Forty-three patients (86 per cent) were treated with physostigmine before rivastigmine administration. Twenty-two were managed with transdermal rivastigmine (most commonly 9.5 mg/24 hour patch), and 28 with oral rivastigmine 6 mg. Further parenteral sedation and/or physostigmine treatment were required more often in patients given transdermal than oral rivastigmine [16/22 (73 per cent) versus 9/28 (32 per cent), P = 0.010)]. No patients had bradycardia or gastrointestinal symptoms following rivastigmine administration. One patient with a history of epilepsy had a seizure, 1.5 hours post physostigmine administration and 7 hours post transdermal rivastigmine.
DISCUSSION: Rivastigmine has been increasingly used for the management of patients with anticholinergic delirium, due to the lack of availability of physostigmine. In this case series, rivastigmine transdermal patch appeared to be less effective than oral rivastigmine capsules, likely due to its slow onset of action and/or insufficient dose.
CONCLUSION: Rivastigmine can be used to treat anticholinergic delirium. In our case series oral rivastigmine appeared more effective than transdermal rivastigmine.
PURPOSE: A novel Arcobacter spp. is provided to effectively develop diagnostic reagent and prevention formulation. CONSTITUTION: A novel Arcobacter spp. is culturable at 35-40°C and under the aerobic condition. The Arcobacter is Arcobacter butzleri CAU090014(KACC91489P), Arcobacter skirrowii CAU090017(KACC91490P), or Arcobacter cryaerophilus CAU090029(KACC91491P). A composition for detecting Arcobacter contains an agent which specifically binds to components of Arcobacter. A composition for preventing and treating food poisoning contains the antibody with respect to Arcobacter or component thereof.